GLYC News and Press, GlycoMimetics Inc. From 12/28/22

Whether you’re looking for the best penny stocks to buy now or just putting together a watch list, research is the first place to begin. Understanding why specific stocks are moving the way they are can help when applying your trading strategy to the stock market today. That’s b...

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two investigator-sponsored trials studying uproleselan in patients with acute myeloid leukemi...

Summary GlycoMimetics stock price jumped on November 9. Good cancer survival results may have lengthened the timeline for a trial readout. The FDA recently allowed for a Q1 2023 interim analysis of uproleselan for AML. GlycoMimetics ( GLYC ) is a clinical-stage b...

GlycoMimetics, Inc. (GLYC) Q3 2022 Earnings Conference Call November 09, 2022, 08:30 AM ET Company Participants Christian Dinneen-Long - Company Counsel Harout Semerjian - President and Chief Executive Officer Brian Hahn - Senior Vice President and Chief Financia...

GlycoMimetics press release ( NASDAQ: GLYC ): Q3 GAAP EPS of -$0.16 beats by $0.10 . As of September 30, 2022, GlycoMimetics had cash and cash equivalents of $51.6 million as compared to $90.3 million as of December 31, 2021. For further details see: GlycoMim...

U.S. Food and Drug Administration (FDA) clears protocol amendment to conduct an interim utility analysis of pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML) Blinded pooled survival data show patients in the Phase 3 study continue to live lon...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that management will participate in two upcoming investor conferences. The Stifel 2022 Healthcare Conference on November 15, 2022 – management will attend and host 1x1 investor meetings. The Jefferies London Healthcare Co...

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that data from two investigator-sponsored trials studying uproleselan in patients with acute mye...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter financial results on Wednesday, November 9, 2022, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provide...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24 th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET. An archived recording of t...